NIH, NVIDIA to develop AI tools for brain, liver cancer clinical trials

The National Institutes of Health (NIH) and tech company NVIDIA are partnering to create AI tools for clinical trials focused on brain and liver cancer.

NVIDIA, based on Santa Clara, California, announced the partnership in a blog post on Nov. 26. Together, the two will focus on developing AI tools that combine imaging, genomic and clinical data to deliver precision medicine to cancer patients, the announcement stated.

“Applying a powerful tool such as deep learning to medicine will require a truly multidisciplinary team of physicians, hospitals and computer scientists to work together to help realize the potential of computer models for medical imaging, and to help develop predictive imaging biomarkers,” Elizabeth Jones, MD, director of the Radiology and Imaging Sciences Department at the NIH Clinical Center, said in a prepared statement.

The company hopes the AI tools will “transform” the current process to measure a tumor and determine cancer stages by automatically characterizing and measuring tumors. Researchers will also focus on using AI to incorporate additional data to improve the accuracy of cancer staging.


In October, NVIDIA announced a partnership with the Scripps Research Translational Institute in a push to apply AI with digital health sensor data.

Through that partnership, the two plan to push disease prevention and detection by applying AI and deep learning best practices, tools and infrastructure to genomics and digital health sensors and work to establish a center of excellence for AI in genomics and digital sensors through the partnership.